![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0029.png)
28
28
Diretrizes AMB
allocation[mesh Terms] OR therapeutic use[mesh
Subheading]
OR
Comparative
study
OR
Epidemiologic methods)
PICO 3
A
ANTICOAGULAÇÃO POR TEMPO INDETERMINADO ESTÁ
INDICADA EM PACIENTES COM
SAF
COM PASSADO DE
TROMBOSE ARTERIAL
? Q
UAL DEVE SER O
INR
ALVO
?
(Antiphospholipid
Syndrome
OR
Anti-
Phospholipid
Antibody
Syndrome
OR
Antiphospholipid Antibody Syndrome OR Anti-
Phospholipid
Syndrome
OR
Antibodies,
Antiphospholipid ) AND ( Anticoagulants OR
Coumarins OR Heparin OR INR) AND (Embolism
and Thrombosis OR Arterial Occlusive Diseases)
AND
((clinical[Title/Abstract]
AND
trial[Title/Abstract]) OR clinical trials[mesh Terms]
OR
clinical
trial[Publication
Type]
OR
random*[Title/Abstract]
OR
random
allocation[mesh Terms] OR therapeutic use[mesh
Subheading]
OR
Comparative
study
OR
Epidemiologic methods)
PICO 4
A
ANTICOAGULAÇÃO POR TEMPO INDETERMINADO ESTÁ INDICADA EM
PACIENTES COM
SAF
QUE APRESENTEM SOMENTE EVENTOS
OBSTÉTRICOS
?
E
A ANTIAGREGAÇÃO PLAQUETÁRIA
?